![]() |
Off-Label Antidepressant Use in Pediatric Patients with...
November 1, 2014 - Clinical , Featured By: Jacqueline Meaney, PharmD Candidate c/o 2015, University at Buffalo: School of Pharmacy and Pharmaceutical Sciences — Psychotropic medications are typically used in conjunction with cognitive behavioral therapy to treat behavioral problems that affect children with autism spectrum disorder (ASD). Symptoms of ASD typically include a need for routines (change intolerance), difficulty with verbal and… |
![]() |
Pradaxa® vs Warfarin...
November 1, 2014 - Featured , In the News / Politics By: Kevin Lin, PharmD Candidate c/o 2015 — The FDA recently completed an observational cohort study that compared Pradaxa® (dabigatran) to warfarin for rates of ischemic stroke, intracranial hemorrhage, major gastrointestinal bleed, myocardial infarction, and death. The study enrolled more than 134,000 patients, with 64% over the age of 65 and found a lower risk… |
![]() |
FDA-Approved Afrezza: An Inhaled Alternative to Injecta...
October 1, 2014 - Featured , In the News / Politics By: Elissa Tam, PharmD Candidate c/o 2015 – Patients with Type 1 or Type 2 diabetes who cannot control their glucose levels simply by taking oral medications have to inject insulin daily. They also have to measure their glucose levels by using strips and lancets on a regular basis. For patients, especially elderly ones, the… |
![]() |
In Wine There Is Truth...
October 1, 2014 - Featured , In the News / Politics By: Katharine Cimmino, Editor-in-Chief – Many articles and quick one-line stories have been cropping up on the internet boasting the benefits of drinking wine regularly. While headlines such as, “Drinking a Glass of Red Wine is the same as Getting an Hour of Exercise, Says New Study,” may make readers ecstatic that their drinking habits… |
![]() |
HIV Pre-Exposure Prophylaxis...
September 1, 2014 - Clinical , Featured By: Elissa Tam PharmD Candidate c/o 2015 – HIV/AIDS continues to be a persistent problem in the United States and in various countries around the world. In 2010 alone, there were around 47,500 new HIV infections in the United States with about 1.1 million Americans living with HIV at the end of 2010.1 When left… |
![]() |
Reservoir of Migraine Therapies Includes Analgesics, AE...
September 1, 2014 - Clinical , Featured By Davidta Brown, Senior Staff Editor – The pain, nausea, and light or sound sensitivity that comprise a migraine attack afflict more than 10% of individuals around the world, easily making migraines one of the most globally debilitating diseases of the present day.1 According to the International Headache Society (IHS), migraines are defined by both… |
![]() |
Migraine Relief at the Push of a Button...
August 1, 2014 - Featured , In the News / Politics By: Davidta Brown, Senior Staff Editor – A new therapeutic device has seemingly leapt from the pages of a science fiction novel and into the hands of migraine sufferers around the world. Worn over the forehead and sending electromagnetic stimulation directly into the supraorbital trigeminal nerves, the cranial nerve stimulator offered by Belgian biotechnology company… |
![]() |
Quantifying the Benefits of Pharmacist Prescribing Powe...
July 1, 2014 - Featured , Professional Advice / Opinions By Davidta Brown, Senior Staff Editor – The idea of granting pharmacists the right to prescribe, as well as to counsel and dispense, has long been a source of controversy among healthcare professionals. A study out of the University of Alberta in Canada, published online in mid-April, provided some much needed concrete data for an… |
![]() |
Grastek®: FDA Approves New Sublingual Immunotherapy fo...
July 1, 2014 - Featured , In the News / Politics By: Kevin Lin, PharmD Candidate c/o 2015 – This April, the FDA approved three sublingual immunotherapies for pollen induced allergic rhinitis: Grastek® (Timothy Grass Pollen Allergen Extract), Oralair® (Grass Pollen Allergen Extract), and Ragwitek® (Short Ragweed Pollen Allergen Extract). Formulated by Merck, Grastek® is Timothy grass pollen allergen extract. It is approved for patients ages… |
![]() |
Scientists Finally Discover How HIV Progresses to AIDS...
June 1, 2014 - Featured , In the News / Politics By: Sabrina Ahmed, PharmD Candidate c/o 2017 – Over the decades, one of the biggest mysteries encountered by researchers has been why so many CD4 T-cells die when one is infected with Human Immunodeficiency Virus (HIV).1 CD4 T-cells are an integral part of the immune system as they locate pathogens and signal other immune cells… |
![]() |
FDA Approves Drug Elosulfase Alfa (Vimizim™) for Muco...
May 1, 2014 - Featured , In the News / Politics By: Erica Dimitropoulos Co-Copy Editor [Content- Focused] – On February 14, 2014, elosulfase alfa (Vimizim™) became an FDA-approved enzyme replacement therapy for Morquio A Syndrome, a type of mucopolysaccharidosis (MPS IVA).1 Elosulfase alfa was granted priority review and was also the first drug to receive the Rare Pediatric Disease Priority Review Voucher that motivates the development… |
![]() |
The Use of Topical Opioid Treatment for Pressure Ulcer ...
May 1, 2014 - Clinical , Featured By: Katharine Cimmino, Editor-in-Chief – Pressure ulcers can be a painful condition decreasing the quality of life of patients and prolonging hospital stays.1 About 10% of hospital inpatients and 26% of hospice admissions have pressure sores.2 Pressure ulcers are injuries that occur when pressure is applied for prolonged periods of time over bony prominences.1 There… |
![]() |
New Strides in Lupus Treatment...
April 1, 2014 - Featured , In the News / Politics By: Daniel Mathan, PharmD Candidate c/o 2016, Anita Kachappilly, PharmD Candidate c/o 2016, & Amrita Singh, PharmD Candidate c/o 2015 – Systemic lupus erythematosus (SLE) is a debilitating autoimmune disease that affects multiple organs in the body and can potentially become life threatening.1 The incidence of SLE is about 50 cases for every 100,000 people; it… |
![]() |
Tasimelteon (Hetlioz®): First FDA Approved Pharmacolo...
April 1, 2014 - Featured , In the News / Politics By: Beatrisa Popovitz, Senior Staff Editor – On January 31st 2014, the FDA announced the release of a revolutionary new drug, tasimelteon (Hetlioz®). Tasimeleton is the first developed treatment of non-24-hour sleep-wake cycle syndrome in blind individuals.1 Formulated by Vanda Pharmaceuticals Inc., this melatonin receptor agonist works by binding to and activating the MT1 and… |
![]() |
Low Literacy and Medication Management?...
February 1, 2014 - Professional Advice / Opinions By: Jenny Park, Pharm. D. Candidate c/o 2015 – As the Affordable Care Act brings health care to many people who are currently uninsured, healthcare providers should expect an increase in the number of patients who don’t understand their plan, disease states, and medications. Health literacy is defined as “the degree to which individuals have… |
![]() |
Dengue Fever: Where Do We Go From Here?...
February 1, 2014 - In the News / Politics By: Sherin Pathickal, PharmD Candidate c/o 2016 – Dengue Fever, widely known as “break-bone fever,” is an illness that causes pain in the joints and muscles, and is often described by those infected as comparable to the feeling of breaking a bone.1 It is spread by mosquitoes and has a painful array of symptomology such… |
![]() |
New Alternative First Line Therapy for EGFR NSCLC...
January 1, 2014 - In the News / Politics By: Jenny Park, PharmD Candidate c/o 2015 – On July 12, 2013, the FDA approved afatinib (GilotrifTM) as a new first-line treatment for patients with late-stage non-small cell lung cancer (NSCLC), a type of carcinoma where specific types of epidermal growth factor receptor (EGFR) gene mutations are expressed.1 The drug afatinib irreversibly blocks EGFR, also… |
![]() |
New Hepatitis C Drug Receives FDA Approval...
January 1, 2014 - Clinical , Featured By: Ada Seldin, Staff Editor – On November 22, 2013, simeprevir (Olysio®), a new agent to treat chronic hepatitis C, received approval under the FDA’s priority review program. Simeprevir is an NS3/4A protease inhibitor that blocks the replication of the hepatitis C virus. Two other drugs from the same class, boceprevir and telaprevir, which were… |
![]() |
The Blunt Truth...
January 1, 2014 - Featured , In the News / Politics By: Katharine Cimmino, Editor-in-Chief – Marijuana, also known as “grass,” “pot,” “joint,” “weed,” “reefer,” “hashish,” and “Mary Jane,” is a very popular illicit drug.1 According to the National Survey on Drug Use and Health, “In 2012, 5.4 million persons aged 12 or older used marijuana on a daily or almost daily basis in the past 12… |
![]() |
Direct Association of HIV and Early Kidney Damage in Wo...
January 1, 2014 - Featured , In the News / Politics By: Elizabeth Kopec, PharmD Candidate c/o 2014, South University School of Pharmacy at Columbia, SC – Human immunodeficiency virus (HIV) is a global pandemic, with approximately 35.3 million people infected in 2012. The United States currently has 1.3 million people living with HIV, with 20,000 deaths occurring every year due to acquired immune deficiency syndrome… |
![]() |
Ponatinib Taken Off the Market...
December 1, 2013 - In the News / Politics By: Sherine Jaison, PharmD Candidate c/o 2015 – The leukemia chemotherapy drug ponatinib (Iclusig) has just been taken off the market. The drug was under investigation by the Food and Drug Administration (FDA) following several reports of serious and life threatening blood clots and narrowing of the blood vessels.1 Ponatinib is a BCR-ABL tyrosine kinase… |
![]() |
Possible Mandatory Lung Cancer Screening...
December 1, 2013 - Featured , In the News / Politics By: Jenny Park, PharmD Candidate c/o 2015 – Lung cancer takes away the lives of about 160,000 individuals annually, which is more than a quarter of all cancer deaths.1 The U.S Preventive Service Task Force is now recommending lung cancer screenings for heavy smokers which could save up to 20,000 lives a year (or about 13%… |
![]() |
Advancements Towards a Malaria Vaccine...
November 1, 2013 - In the News / Politics By: Sang Hyo Kim, Staff Editor – A new experimental vaccine, PfsPZ, offers great promise as a cure for malaria. PfsPZ demonstrated 100% success in protecting subjects from this mosquito-borne tropical disease, which affects about 200 million people and causes 660,000 death annually.1,2 Historically, it has been known that sustained immunity for malaria could be… |
![]() |
New Treatment for a Deficiency in Iron-Supplement Thera...
October 1, 2013 - Clinical By: Davidta Brown, Staff Editor – For the estimated 7.5 million individuals in the United States living with iron deficiency anemia (IDA), there is now a new alternative to iron supplements or time-consuming, repetitive infusions. On July 25, 2013, the FDA approved ferric carboxymaltose injection (Injectafer®) for the treatment of IDA, especially in patients who… |
![]() |
New Drug to Treat HIV-1 Hits the Market...
October 1, 2013 - Clinical , Featured By: Ada Seldin, Staff Editor – On August 12,2013, a new weapon against HIV-1 infection was added to the existing armada. Dolutegravir, the third integrase strand transfer inhibitor to attain FDA approval, targets a protein essential to HIV replication. HIV-1 is the predominant type of HIV virus, the other being HIV-2, which is endogenous to… |
![]() |
Hope For Children with Acute Lymphoblastic Leukemia...
October 1, 2013 - Featured , In the News / Politics By: Ada Seldin, Staff Editor – Emily Whitehead, a 7-year-old girl who fought off relapsing acute lymphoblastic leukemia (ALL), has captured the hearts and prayers of the masses. Her story is an inspiration to those battling any disease with a poor prognosis and particularly holds promise for the 15% of children with ALL resistant to… |
![]() |
Nattokinase use in DVT prophylaxis...
October 1, 2013 - Clinical Samad Tirmizi, Pharm. D. Candidate c/o 2014 – Deep vein thrombosis (DVT) is a clot formation that occurs within deep veins, generally in the legs. This can cause swelling and pain due to the engorged vessels, and can eventually result in further complications such as a pulmonary embolism. Patients at high risk for DVT are… |
![]() |
A Close Concurrence on Certolizumab (Cimzia®)...
September 1, 2013 - Clinical , Featured By: Sang Hyo Kim, Staff Editor – This year, on July 23rd, FDA advisers voted 7 to 6, with one abstention, in favor of approving the drug certolizumab (Cimzia®) for the indication of axial spondyloarthritis (axSpA). axSpA is a chronic imflammatory condition that includes ankylosing spondylitis (AS) and non-radiographic axial spndyloarthristis (nr-axSpA).1,2 axSpA, AS and… |
![]() |
Two New Agents for the Treatment of Obesity...
August 1, 2013 - Clinical , Featured By: Nathan Trustman, PharmD Candidate c/o 2013, AMSCOP at LIU – Obesity is defined as having a body mass index (BMI) of 30 kg/m2 or greater. It is thought to be the result of an imbalance between energy intake and energy expenditure, possibly due to a number of genetic and environmental factors.1 It is estimated… |
![]() |
Solving the HCV Enigma: Current and Future Drug Therapy...
July 1, 2013 - Clinical , Featured By: Tamara Yunusova, Senior Staff Editor – Approximately 3.2 million Americans have chronic hepatitis C infection.1 While acute cases are not common, rates of chronic hepatitis C continue to surge due to the recent discovery of the virus in 1989 and consequently, the establishment of a test screening for HCV antibodies in 1992.1 HCV has… |
![]() |
Angelina Jolie’s Double Mastectomy: What it Reveals A...
July 1, 2013 - Professional Advice / Opinions By Sang Hyo Kim, Staff Editor – Angelina Jolie, the actress recognized for her charismatic beauty, revealed to the New York Times that she had undergone double mastectomy, the surgical removal of the breasts. Because her mother died of ovarian cancer at 56, when Jolie learned that she had a mutation in her BRCA1 gene,… |
![]() |
Helping Solve the Cruel Mystery...
June 1, 2013 - Featured , In the News / Politics By: Erica Dimitropoulos, Senior Staff Editor – Lupus is highly unpredictable and occurs without warning; there is no known cause and no known cure. It affects over 1.5 million Americans, 90% of whom are women between the ages of 15 – 44.1 No two cases of lupus are alike, making it a very difficult disease… |
![]() |
Pay to Delay: The Honest Truth...
June 1, 2013 - Professional Advice / Opinions By: David Ong, Pharm.D. Candidate c/o 2014 – Our current healthcare system receives much criticism from the press as well as the public. Big pharmaceutical companies (“Big Pharma”) have consistently been characterized as part of the problem. Most of the blame for high drug costs is levied on Big Pharma. One of the criticisms is… |
![]() |
FDA Approves Dimethyl Fumarate for Treatment of Relapsi...
June 1, 2013 - Clinical , Featured By: Andy Zhang, PharmD Candidate c/o 2015 – On March 28, 2013, the U.S. Food and Drug Administration announced the approval of Tecfidera™ (dimethyl fumarate) for the treatment of relapsing forms of multiple sclerosis (MS) in adults.1 Tecfidera™ (dimethyl fumarate) will be the third oral drug used for the treatment of MS. The manufacturer Biogen… |
![]() |
Disclosure of Clinical Research Funding: Can Ignorance ...
May 1, 2013 - Professional Advice / Opinions By: Bharat Kirthivasan, Co-Copy Editor [Content-Focused] – Most people would prefer that a research paper be mandated to disclose its source of funds. For example, if a publication effusively supports a certain drug, we want to know if its parent company is footing the bill. Transparency allows research to be viewed in light of its… |
![]() |
Regulation of Low to Moderate Risk Medical Devices by t...
May 1, 2013 - Featured , Professional Advice / Opinions By: Hayeon Na, Co-Copy Editor [Content-Focused] – On March 22, 2013, Public Broadcasting Service (PBS) aired an episode of “Need to Know” on the safety of low to moderate risk medical devices. The episode closely followed the lawsuit of patient Linda Gross who has pelvic organ prolapse and was advised by her doctor to undergo… |
![]() |
Merck Settles Lawsuits Over Vytorin...
April 1, 2013 - In the News / Politics By: Tasnima Nabi, Staff Editor – Merck & Co. will pay $688 million to settle two lawsuits filed in December 2008 over their patent-protected statin, Vytorin®. The suits state that Merck and Schering-Plough delayed releasing the results of their ENHANCE study to avoid a decrease in revenue.1 Vytorin® is a combination drug of simvastatin and… |
![]() |
Increased Costs of Treatment due to the DSM-V: Implicat...
April 1, 2013 - Featured , In the News / Politics By: James W. Schurr and David Gao, PharmD Candidates 2014 – A recent Op-ed in Newsday by Allen Frances, MD (of Duke University School of Medicine and chairman of the task force that produced the DSM-IV, the current guidelines for psychiatric disease diagnosis) criticizes the American Psychiatric Association for being “extravagantly indifferent to all matters… |
![]() |
New P2Y12 Antagonist on the Rise...
April 1, 2013 - Clinical By Nancy Rizkalla, PharmD candidate c/o 2015 – Percutaneous coronary intervention (PCI) with subsequent stent implantation is a highly effective approach in reducing the risk of death or ischemic complications following a myocardial infarction as well as improving the quality of life in patients with stable angina. PCI is ultimately performed in 60 –… |
![]() |
FDA Approves New Indication for Botox (Onabotulinumtoxi...
March 1, 2013 - Clinical , Featured By: Bethsy Jacob, PharmD Candidate 2014 – On January 18, 2013, the U.S. Food and Drug Administration (FDA) announced a new approval for Botox, generically known as OnabotulinumtoxinA. Patients diagnosed with urinary incontinence due to an overactive bladder can be prescribed Botox, if they are unable to take or are unresponsive to anticholinergic medications. This… |
![]() |
Liraglutide (Victoza®) for Type 2 Diabetes Mellitus...
February 1, 2013 - Clinical , Featured By: Miriam Maltz, PharmD Candidate c/o 2013, AMSCOP, Long Island University – Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by hyperglycemia that is pursuant to insulin resistance, defects in insulin secretion, or both1. Chronic hyperglycemia is associated with detrimental effects on various organ systems that can increase mortality and impact the patient’s… |
![]() |
Emerging Pathways For Treating Hepatitis C Virus...
February 1, 2013 - Clinical , Featured By: Maria Sorbera, PharmD Candidate c/o 2013, AMSCOP, LIU – Hepatitis C is the leading cause of chronic liver disease and cirrhosis, presenting a global health challenge. Approximately 170 million people worldwide, 3% of the population, are infected with the Hepatitis C Virus (HCV), roughly 3.2 million of whom reside in the United States. The… |
![]() |
FDA Approves Apixaban For Nonvalvular Atrial Fibrillati...
January 1, 2013 - Clinical , Featured , In the News / Politics By: Alexandra Alleva, PharmD candidate c/o 2013 – As of December 28th, Bristol-Myers Squibb and Pfizer’s brand name oral anticoagulant, Eliquis® (apixaban), attained FDA approval.1 This occurred one month after its approval in Europe and Canada, following longer than expected waits in the US due to further investigation requests by the FDA.2 The much-anticipated anticoagulant is… |
![]() |
Safety and Efficacy of Atropine for Salivary Hypersecre...
November 1, 2012 - Clinical By: Elsa Thomas, PharmD Candidate c/o 2013 – Atropine is an anticholinergic used to treat various conditions, such as bradycardia, neuromuscular blockade, mydriasis, nerve agent poisoning, and salivary hypersecretion.1,2 Pharmacologically, it inhibits smooth muscle and glands innervated by postganglionic cholinergic nerves.1,2 It also has functions in the central nervous system (CNS); it could stimulate or… |
![]() |
New Drug Review: Tofacitinib (Xeljanz®)...
November 1, 2012 - Clinical By: Jessica Lee, PharmD Candidate c/o 2013 – Rheumatoid arthritis (RA) is an autoimmune disease in which the immune system attacks healthy tissue, causing inflammation of the joints and potential harm to other organs.1 It affects 0.5-1% of the adult population and is more prevalent in the seventh decade of life.1 These patients tend to… |
![]() |
Low-dose SSRIs for the Overly Sensitive Esophagus...
November 1, 2012 - Clinical , Featured By Sunhae Chang, PharmD Candidate c/o 2013 – When patients complain of heartburn, the blame usually shifts to gastroesophageal reflux disease (GERD). Therefore, patients receive the “standard therapies for GERD”: antacids, histamine-2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), or prokinetics.1,2 Luckily, most patients respond well to these agents.1,2 Unfortunately, the not-as-lucky ones, despite PPI… |
![]() |
Duloxetine’s Effect on Blood Glucose Levels...
October 1, 2012 - Clinical , Featured By: Neal Shah, Co-Editor-in-Chief – Duloxetine is a serotonin (5HT) and norepinephrine (NE) reuptake inhibitor (SNRI) introduced to the US market in 2004, indicated for the treatment of diabetic neuropathic pain.1 A chemical figure of duloxetine is shown [in the PDF].2 It was developed in an effort to mimic tricyclic antidepressant mitigation of neuropathic pain… |
![]() |
The Role of NMDA in Electroconvulsive Therapy and Other...
October 1, 2012 - Clinical , Featured By: Neal Shah, Co-Editor-in-Chief – Electroconvulsive therapy (ECT) is a last-line procedure in the treatment of refractory depression, among other neuropsychological disorders.1 By inducing a seizure, neurotransmitters are released and the disease state may feature a modest mitigation in symptoms.1 Seizure medications such as benzodiazepines and barbiturates are prescribed to increase or heighten the seizure… |
![]() |
Bisphosphonates and Atypical Fracture Risk...
September 1, 2012 - Clinical , Featured By: Steve Soman, Pharm.D. Candidate c/o 2013 – Bisphosphonates are proven to enhance bone density and reduce fracture incidence in post-menopausal women but recent data suggests they may have adverse effects with regards to bone quality. The drugs in this class can be differentiated as non-nitrogen containing (older generation) and nitrogen containing (newer generation) medications.… |
![]() |
Antiplatelet Use Following Acute Coronary Syndromes...
September 1, 2012 - Clinical , Featured By: Addolorata Ciccone, Co-Copy Editor – Acute Coronary Syndromes Acute coronary syndrome (ACS) is a myocardial ischemia caused by obstruction of coronary arteries. ACS is stratified into three types, based on electrocardiogram (EKG) changes and the presence of cardiac biomarkers (e.g. troponin, creatinine phosphokinase, and myoglobin). To guide treatment plans, it is important to identify… |